NYSE:MRK - Merck & Co., Inc. Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$76.48 -1.97 (-2.51 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$76.48
Today's Range$76.23 - $78.03
52-Week Range$52.83 - $80.19
Volume13.26 million shs
Average Volume11.64 million shs
Market Capitalization$206.20 billion
P/E Ratio19.22
Dividend Yield2.51%
Beta0.71
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., and Daiichi Sankyo Company, Limited. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:MRK
Previous Symbol
CUSIP58933Y10
Phone908-740-4000

Debt

Debt-to-Equity Ratio0.61
Current Ratio1.44
Quick Ratio1.15

Price-To-Earnings

Trailing P/E Ratio19.22
Forward P/E Ratio17.62
P/E Growth2.08

Sales & Book Value

Annual Sales$40.12 billion
Price / Sales5.14
Cash Flow$5.7160 per share
Price / Cash Flow13.38
Book Value$12.69 per share
Price / Book6.03

Profitability

EPS (Most Recent Fiscal Year)$3.98
Net Income$2.39 billion
Net Margins8.44%
Return on Equity34.48%
Return on Assets13.42%

Miscellaneous

Employees69,000
Outstanding Shares2,696,190,000
Market Cap$206.20 billion
OptionableOptionable

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Thursday, October 25th. Shareholders of record on Monday, December 17th will be given a dividend of $0.55 per share on Tuesday, January 8th. This represents a $2.20 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date is Friday, December 14th. This is a positive change from Merck & Co., Inc.'s previous quarterly dividend of $0.48. View Merck & Co., Inc.'s Dividend History.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. declared that its Board of Directors has approved a stock buyback plan on Thursday, October 25th 2018, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 5.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its shares are undervalued.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Thursday, October, 25th. The company reported $1.19 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.14 by $0.05. The company had revenue of $10.79 billion for the quarter, compared to the consensus estimate of $10.87 billion. Merck & Co., Inc. had a net margin of 8.44% and a return on equity of 34.48%. View Merck & Co., Inc.'s Earnings History.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, February 1st 2019. View Earnings Estimates for Merck & Co., Inc..

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Friday, February 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2018 earnings guidance on Thursday, October, 25th. The company provided earnings per share (EPS) guidance of $4.30-4.36 for the period, compared to the Thomson Reuters consensus estimate of $4.29. The company issued revenue guidance of $42.1-42.7 billion, compared to the consensus revenue estimate of $42.46 billion.

What price target have analysts set for MRK?

15 brokerages have issued 1 year price objectives for Merck & Co., Inc.'s shares. Their forecasts range from $58.83 to $86.00. On average, they expect Merck & Co., Inc.'s stock price to reach $73.53 in the next twelve months. This suggests that the stock has a possible downside of 3.9%. View Analyst Price Targets for Merck & Co., Inc..

What is the consensus analysts' recommendation for Merck & Co., Inc.?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merck & Co., Inc..

Has Merck & Co., Inc. been receiving favorable news coverage?

News coverage about MRK stock has trended somewhat positive on Sunday, according to InfoTrie. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a decrease in short interest during the month of November. As of November 30th, there was short interest totalling 64,470,981 shares, a decrease of 6.6% from the November 15th total of 69,025,249 shares. Based on an average trading volume of 12,612,964 shares, the days-to-cover ratio is presently 5.1 days. Approximately 2.5% of the company's stock are short sold. View Merck & Co., Inc.'s Current Options Chain.

Who are some of Merck & Co., Inc.'s key competitors?

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the folowing people:
  • Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)
  • Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)
  • Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)
  • Ms. Rita A. Karachun, Principal Accounting Officer, Sr. VP of Fin. & Global Controller (Age 54)

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.52%), Vanguard Group Inc (7.52%), BlackRock Inc. (6.83%), Capital World Investors (3.24%), Franklin Resources Inc. (1.49%) and Bank of New York Mellon Corp (1.45%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, C Robert Kidder, Julie L Gerberding, Kenneth C Frazier, Merck & Co, Inc, Michael J Holston, Patricia F Russo, Richard R Deluca, Rita A Karachun, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

Which institutional investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Franklin Resources Inc., Mitsubishi UFJ Trust & Banking Corp, Dodge & Cox, Dodge & Cox, HealthCor Management L.P., Canada Pension Plan Investment Board and BlackRock Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Ashley Watson, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Richard R Deluca, Rita A Karachun, Roger M Perlmutter, Sanat Chattopadhyay, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

Which institutional investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Capital International Investors, Janus Henderson Group PLC, Matthew Goff Investment Advisor LLC, Capital Research Global Investors, Third Point LLC, TIAA CREF Investment Management LLC and Alliancebernstein L.P.. View Insider Buying and Selling for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $76.48.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $206.20 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is http://www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]


MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  689 (Thanks for Voting!)
Underperform Votes:  721 (Thanks for Voting!)
Total Votes:  1,410
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel